CRSP — CRISPR Therapeutics AG price, chart and key statistics

Price data

Price

$49.25

YTD price return

-6.08%

YTD total return

-6.08%

Next earnings

Nov 9, 2026

Market cap

4.8B2016-12 806.5M2026-10 4.8B+490.8% over the window

Enterprise value

3.2B

Shares outstanding

96.7M2016-06 5.4M2026-06 96.7M+1674.5% over the window

52W low

$44.12

52W high

$75.06

From 52W high

-34.39%

From 52W low

+11.63%

52W range

17%

Volume

Rel volume

0.91×

30D volume

1.7M

30D $ vol

89.8M

Fundamentals

Sales (ttm)

13.4M2016-09 3.1M2026-06 13.4M+336.6% over the window

Sales/share

$0.142016-09 $0.082026-06 $0.14+79.8% over the window

EPS (ttm)

-$4.762016-06 -$8.122026-06 -$4.76-41.4% over the window

FCF (ttm)

-371.3M2016-09 29.8M2026-06 -371.3M-1345.3% over the window

FCF/share

-$3.842016-09 $0.752026-06 -$3.84-612.7% over the window

Book value/share

$18.062016-09 -$1.572026-06 $18.06-1250.9% over the window

Net margin

-3368.72%2016-09 -1713.3%2026-06 -3368.7%+96.6% over the window

ROE

-25.83%2016-12 -10.0%2026-06 -25.8%+159.5% over the window

ROA

-17.02%2016-09 -18.9%2026-06 -17.0%-9.7% over the window

Debt / equity

0.34×2025-12 0.002026-06 0.34

Current ratio

17.852016-09 2.972026-06 17.85+501.7% over the window

Growth (CAGR, ttm) · 10Y

Sales

-64.83%2025-06-30 → 2026-06-3038M → 13.4M (-64.8% total)-57.13%2023-06-30 → 2026-06-30170.1M → 13.4M (-92.1% total)-56.92%2021-06-30 → 2026-06-30901.8M → 13.4M (-98.5% total)+16.33%2016-09-30 → 2026-06-303.1M → 13.4M (+336.6% total)

Shares

+6.32%2025-06-30 → 2026-06-3091M → 96.7M (+6.3% total)+6.78%2023-06-30 → 2026-06-3079.4M → 96.7M (+21.8% total)+4.88%2021-06-30 → 2026-06-3076.2M → 96.7M (+26.9% total)+33.33%2016-06-30 → 2026-06-305.4M → 96.7M (+1674.5% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share

-66.92%2025-06-30 → 2026-06-30$0.42 → $0.14 (-66.9% total)-59.85%2023-06-30 → 2026-06-30$2.14 → $0.14 (-93.5% total)-58.92%2021-06-30 → 2026-06-30$11.83 → $0.14 (-98.8% total)+6.20%2016-09-30 → 2026-06-30$0.08 → $0.14 (+79.8% total)

Book value/share

-3.99%2025-06-30 → 2026-06-30$18.81 → $18.06 (-4.0% total)-7.56%2023-06-30 → 2026-06-30$22.87 → $18.06 (-21.0% total)-11.97%2021-06-30 → 2026-06-30$34.17 → $18.06 (-47.1% total)n/a

Price

-28.04%2025-10-16 → 2026-10-16$68.43 → $49.25 (-28.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+3.20%2023-10-16 → 2026-10-16$44.81 → $49.25 (+9.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-12.67%2021-10-15 → 2026-10-16$97.00 → $49.25 (-49.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+13.34%2016-10-19 → 2026-10-16$14.09 → $49.25 (+249.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.

Total return

-28.04%2025-10-16 → 2026-10-16$68.43 → $49.25 (-28.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+3.20%2023-10-16 → 2026-10-16$44.81 → $49.25 (+9.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-12.67%2021-10-15 → 2026-10-16$97.00 → $49.25 (-49.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+13.34%2016-10-19 → 2026-10-16$14.09 → $49.25 (+249.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.

-10.3×2016-12 -15.352026-10 -10.56-31.2% over the window

Fwd P/E

-15.3×

P/S (ttm)Market cap ÷ TTM revenue.

355.6×2016-12 262.972026-10 355.81+35.3% over the window

P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.

2.7×2016-12 -12.912026-10 2.73-121.1% over the window

EV/Sales (ttm)

238.3×

FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.

-7.80%2016-09 3.7%2026-06 -7.0%-290.4% over the window

Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 96.7M ÷ 91.0M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.

-6.32%

Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-6.32%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($4.4B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.

-6.32%

Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-388.9M) ÷ today's market cap ($4.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.

-8.17%2016-09 -0.0%2026-06 -7.4%+371605.4% over the window

Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-388.9M + TTM dividends $0) ÷ today's market cap ($4.8B). Same caveat as the cash buyback yield.

-8.17%2016-09 -0.0%2026-06 -7.4%+371605.4% over the window

Vs own 10Y history

P/S

76th

P/B

37th